Loading stock data…
Integra LifeSciences Holdings C (IART)
$18.74-0.02 (-0.11%)
Market ClosedLast close Jun 29
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Integra LifeSciences Holdings Corporation in the Healthcare sector is trading at $18.74 with a market capitalization of $1.3B. Wall Street consensus targets $17.43 (7 analysts), implying a -7.0% move over the next 12 months. The stock is currently near its 52-week high of $18.92, remaining 45.7% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply -7.0% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $391.92M↓ | $434.93M↑ | $402.06M↓ | $415.61M↑ | $382.65M |
| Gross Profit | $216.98M↓ | $220.87M↑ | $206.99M↓ | $209.33M↑ | $194.43M |
| Operating Income | $11.47M↓ | $23.04M↑ | $11.76M↑ | -$1.31M↑ | -$15.50M |
| Net Income | -$4.62M↓ | -$1.70M↑ | -$5.40M↑ | -$484.07M↓ | -$25.29M |
Peer Comparison
JNJUNHPFE
Fundamentals
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Sur...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.25B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.08
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-47.56%
Volume
Today's trading volume
914,748
Recent News
Is Integra LifeSciences’ New Commercial Structure Recasting Its Execution Story for Investors in IART?
In June 2026, Integra LifeSciences Holdings announced a reshaped commercial leadership team, including new executives to oversee Tissue Reconstruction and Specialty Surgery, following the earlier appointment of a chief commercial officer and a recent investor conference appearance. This consolidation of commercial and international leadership under a single organization signals a clearer focus on execution, portfolio priorities, and customer alignment across Integra’s global...
1 Value Stock to Target This Week and 2 We Brush Off
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason — five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.
Zacks.com featured highlights TPG Mortgage Investment Trust, Silvercorp and Integra LifeSciences
TPG Mortgage Investment Trust, Silvercorp and Integra LifeSciences have been highlighted in this Screen of The Week article.
Surgical Equipment & Consumables - Specialty Stocks Q1 Results: Benchmarking Integra LifeSciences (NASDAQ:IART)
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Integra LifeSciences (NASDAQ:IART) and the rest of the surgical equipment & consumables - specialty stocks fared in Q1.
Bet on These 3 Stocks as Broker Rating Upgrades Signal Upside
MITT, SVM and IART stand out as broker rating upgrades, earnings growth forecasts and screen criteria point to potential upside.